Citation only
via OpenAlex
Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2
Alexander B. Mohseny, Károly Szuhai, Salvatore Romeo, Emilie P. Buddingh, Inge H. Briaire‐de Bruijn, Daniëlle de Jong, Melissa van Pel, Anne‐Marie Cleton‐Jansen, Pancras C.W. Hogendoorn
The Journal of Pathology · 2009 · ▲ 265 citations
Abstract
High-grade osteosarcoma is characterized by extensive genetic instability, thereby hampering the identification of causative gene mutations and understanding of the underlying pathological processes. It lacks a benign precursor lesion and reports on associations with hereditary predisposition or germline mutations are uncommon, despite the early age of onset. Here we demonstrate a novel comprehensive approach for the study of premalignant stages of osteosarcoma development in a murine mesenchymal stem cell (MSC) system that formed osteosarcomas upon grafting. By parallel functional and phenotypic analysis of normal MSCs, transformed MSCs and derived osteosarcoma cells, we provide substantial evidence for a MSC origin of osteosarcoma. In a stepwise approach, using COBRA-FISH karyotyping and array CGH in different passages of MSCs, we identified aneuploidization, translocations and homozygous loss of the cdkn2 region as the key mediators of MSC malignant transformation. We then identified CDKN2A/p16 protein expression in 88 osteosarcoma patients as a sensitive prognostic marker, thereby bridging the murine MSCs model to human osteosarcoma. Moreover, occasional reports in patients mention osteosarcoma formation following bone marrow transplantation for an unrelated malignancy. Our findings suggest a possible hazard for the clinical use of MSCs; however, they also offer new opportunities to study early genetic events in osteosarcoma genesis and, more importantly, to modulate these events and record the effect on tumour progression. This could be instrumental for the identification of novel therapeutic strategies, since the success of the current therapies has reached a plateau phase.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1002/path.2603
- Canonical
- link ↗
- Fetched
- 2026-09-21 MST
Cite this
APA
Mohseny, A.B., Szuhai, K., Romeo, S., Buddingh, E.P., Bruijn, I.H.B., Jong, D.D., Pel, M.V., Cleton‐Jansen, A., & Hogendoorn, P.C. (2009). Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. <em>The Journal of Pathology</em>. https://doi.org/10.1002/path.2603
Vancouver
Mohseny AB, Szuhai K, Romeo S, Buddingh EP, Bruijn IHB, Jong DD, et al. Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. The Journal of Pathology. 2009. doi:10.1002/path.2603.
BibTeX
@article{alexander2009Osteos,
title = {Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2},
author = {Alexander B. Mohseny and Károly Szuhai and Salvatore Romeo and Emilie P. Buddingh and Inge H. Briaire‐de Bruijn and Daniëlle de Jong and Melissa van Pel and Anne‐Marie Cleton‐Jansen and Pancras C.W. Hogendoorn},
journal = {The Journal of Pathology},
year = {2009},
doi = {10.1002/path.2603},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Cancer Research 2013
Open access · OA
Highlights from Recent Cancer Literature
Stem Cell Research & Therapy 2024
Open access · CC-BY
Translational potential of mesenchymal stem cells in regenerative therapies for human diseases: challenges and opportunities
Stem Cell Research & Therapy 2018
Open access · CC-BY
Changes in phenotype and differentiation potential of human mesenchymal stem cells aging in vitro
Frontiers in Medicine 2018
Open access · CC-BY
Mesenchymal Stem Cells for the Treatment of Idiopathic Pulmonary Fibrosis
International Journal of Molecular Sciences 2021
Open access · CC-BY
Therapeutic Properties of Mesenchymal Stromal/Stem Cells: The Need of Cell Priming for Cell-Free Therapies in Regenerative Medicine
Biotechnology Advances 2013
Open access · CC-BY